Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infections, Clostridium Difficile Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

NCT06258551
View directory record Official record
Conditions
Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

NCT03105479
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Cadazolid, Vancomycin capsule, Vancomycin solution
Drug
Lead sponsor
Actelion
Industry
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 3 Interventional Results available

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

NCT04802837
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 22, 2026, 1:58 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

NCT07221708
View directory record Official record
Conditions
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions
Vancomycin (POC)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

NCT03589768
View directory record Official record
Conditions
Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation, Pertussis, Tetanus, Tetanus Immunisation
Interventions
Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

NCT02106338
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Placebo, CRS3123
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Phase 3 Interventional

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02299570
View directory record Official record
Conditions
Enterocolitis Clostridium Difficile Recurrent
Interventions
RBX2660 (microbiota suspension), Placebo
Biological · Other
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

NCT01887912
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
9,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
142
States / cities
Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

NCT02437487
View directory record Official record
Conditions
Clostridium Difficile
Interventions
SER-109, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Oceanside, California • Sacramento, California • Ventura, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 22, 2026, 1:58 AM EDT
Completed No phase listed Observational

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab, Standard CDI treatment
Biological · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 2 Interventional Results available

Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection

NCT01570634
View directory record Official record
Conditions
Diarrhoea, Clostridium Difficile
Interventions
Calcium Aluminosilicate Anti-Diarrheal (CASAD)
Drug
Lead sponsor
Salient Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 4 Interventional

Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury

NCT02355938
View directory record Official record
Conditions
Clostridium Difficile, Spinal Cord Injury
Interventions
Fidaxomicin 200 mg, Placebo, Vancomycin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of a Single Dose of CRS3123

NCT01551004
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
CRS3123, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 22, 2026, 1:58 AM EDT
Not listed No phase listed Observational

Immune Response to C.Difficile Infection

NCT02797288
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 22, 2026, 1:58 AM EDT
Withdrawn Not applicable Interventional

Extended Treatment With Vancomycin for Clostridium Difficile Colitis

NCT00861887
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Standard Vancomycin, Extended Vancomycin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 22, 2026, 1:58 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT05330182
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
LMN-201, Placebo
Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

NCT03621657
View directory record Official record
Conditions
Clostridium Difficile Infection, C.Difficile Diarrhea, CDI
Interventions
Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Not listed Phase 1 Interventional

Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

NCT02134392
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Jonathan Gisser
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 3 Interventional

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

NCT00106509
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions
tolevamer potassium-sodium (GT267-004)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
99
States / cities
Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

Fecal Microbiota Transplantation for C Diff Infection

NCT01905709
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Human fecal matter
Biological
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Phase 2 Interventional

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

NCT04305769
View directory record Official record
Conditions
Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 105 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 22, 2026, 1:58 AM EDT